<circle stroke="#1e77f9" class="srdi68r9" cx="25" cy="25" r="20" fill="none" stroke-width="5">

Nanobiotix price target raised to EUR 23 from EUR 20 at H.C. Wainwright

PremiumThe Fly

27d ago

Nanobiotix’s Strategic Financing and Clinical Expansion Signal Strong Buy Opportunity

PremiumRatings

27d ago

Nanobiotix enters royalty-based financing pact with HealthCare Royalty for $71M

PremiumThe Fly

1M ago

Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer

PremiumThe Fly

1M ago

PremiumThe FlyNanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright

2M ago

Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts

The Fly

Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts

2M ago

Nanobiotix price target raised to EUR 13 from EUR 10 at H.C. Wainwright

The Fly

Nanobiotix price target raised to EUR 13 from EUR 10 at H.C. Wainwright

2M ago

Nanobiotix price target raised to $14 from $9 at Leerink

PremiumThe Fly

2M ago

Nanobiotix announces new results from JNJ-1900 study

PremiumThe Fly

2M ago

Nanobiotix SA – ADR trading resumes

PremiumThe Fly

4M ago

Nanobiotix SA – ADR trading halted, volatility trading pause

PremiumThe Fly

4M ago

PremiumThe FlyNanobiotix announces regulatory harmonization, new patent for JNJ-1900

5M ago

Promising Clinical Developments and Strategic Partnerships Propel Nanobiotix to a Buy Rating

Ratings

Promising Clinical Developments and Strategic Partnerships Propel Nanobiotix to a Buy Rating

6M ago

Nanobiotix’s Strategic Advancements and Financial Strength Bolster Buy Rating

Ratings

Nanobiotix’s Strategic Advancements and Financial Strength Bolster Buy Rating

6M ago

Nanobiotix’s NBTXR3: Promising Survival Benefits and Strategic Collaborations Justify Buy Rating

PremiumRatings

7M ago

Nanobiotix SA’s Positive Earnings Call Highlights Strategic Growth

PremiumCompany Announcements

8M ago

PremiumThe Fly

Nanobiotix price target lowered to $8 from $12 at Guggenheim

8M ago

Nanobiotix’s Promising Future: Buy Rating Backed by Data-Rich 2025 and Strategic Advancements

PremiumRatings

8M ago

PremiumRatingsNanobiotix: Strategic Partnerships and Clinical Advancements Drive Buy Rating

8M ago

Positive Clinical Data and Strategic Partnerships Drive Buy Rating for Nanobiotix

Ratings

Positive Clinical Data and Strategic Partnerships Drive Buy Rating for Nanobiotix

8M ago

Nanobiotix’s Strategic Partnership and Financial Stability Justify Buy Rating

Ratings

Nanobiotix’s Strategic Partnership and Financial Stability Justify Buy Rating

8M ago